Dr. Martens PLC (DOCS)

Currency in GBP
71.50
-0.20(-0.28%)
Closed·
Advertisement
DOCS is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
71.3073.00
52 wk Range
59.35100.80
Key Statistics
Bid/Ask
71.00 / 74.00
Prev. Close
71.7
Open
73
Day's Range
71.3-73
52 wk Range
59.35-100.8
Volume
1.64M
Average Volume (3m)
1.36M
1-Year Change
-8.0386%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
DOCS Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
100.17
Upside
+40.09%
Members' Sentiments
Bearish
Bullish
ProTips
Valuation implies a strong free cash flow yield

Dr. Martens PLC News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Sell
Moving Averages
Sell

Analyst Ratings

3 Buy
3 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 100.17
(+40.09% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Berenberg
Buy1.10+53.85%1.14Maintain20/05/2026
Barclays
Hold0.85+18.88%0.90Maintain21/11/2025
Berenberg
Buy1.14+59.44%-Maintain24/10/2025
RBC Capital
Hold1.00+39.86%0.90Maintain11/08/2025

Dr. Martens PLC Earnings Call Summary for H2/2026

  • Dr. Martens missed Q2 FY2026 EPS forecast by 12.6% (4.23p vs 4.84p expected); revenue fell 0.94% short at £442.95M despite 1.04% stock gain.
  • Adjusted profit before tax surged 61% YoY to £55M on consumer-first pivot; gross margin improved 1.2% through reduced markdown dependency.
  • Americas and APAC regions delivered strong performance while EMEA faced execution challenges; revenue declined 1.4% on constant currency basis.
  • Company provided FY2027-2028 EPS guidance of $1.52 and $1.68 respectively; management emphasized premium product expansion and full-price sales focus.
  • CEO Wilson cited strategic shift benefits; CFO Mortimer highlighted cost controls positioning company for growth despite macroeconomic and supply chain risks.
Last Updated: 21/05/2026, 18:10
Read Full Transcript

Earnings

Latest Release
19/05/2026
EPS / Forecast
0.04 / 0.05
Revenue / Forecast
442.95M / 447.14M
EPS Revisions
Last 90 days

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 0.02%
Dividend Yield
3.56%
Industry Median 2.08%
Annualised payout
2.55
Paid unevenly
5-Years Growth
-
Growth Streak

Compare DOCS to Peers and Sector

Metrics to compare
DOCS
Peers
Sector
Relationship
P/E Ratio
28.8x16.7x10.4x
PEG Ratio
0.070.310.02
Price/Book
1.9x1.3x1.4x
Price / LTM Sales
0.9x0.7x0.9x
Upside (Analyst Target)
36.0%17.1%27.9%
Fair Value Upside
Unlock15.3%11.8%Unlock

Dr. Martens plc engages in the design, development, procurement, marketing, sale, and distribution of footwear. The company sells its footwear under the Dr. Martens brand name in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. Dr. Martens plc was founded in 1945 and is based in London, the United Kingdom.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
328.25M34.30%232.73M
Other Institutional Investors
684.03M65.70%484.98M
Public Companies & Retail Investors
0.000.00%0.00
Total
1.01B100.00%717.7M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Permira Advisers Ltd.38.65%369,942,440262,289
Artemis Investment Management LLP12.44%119,012,10684,380

People Also Watch

5.570
ICAG
-0.14%
281.50
BOWL
-0.18%
847.50
RPI
-2.02%
238.00
FTC
-11.19%
162.00
SPCX
+2.83%

FAQ

What Is the Dr. Martens (London: DOCS) Share Price Today?

The Dr. Martens stock price today is 71.50 GBP.

What Stock Exchange Does Dr. Martens (DOCS) Trade On?

Dr. Martens is listed and trades on the London Stock Exchange.

What Is the Ticker (Stock Symbol) for Dr. Martens?

The stock symbol (also called a 'ticker') for Dr. Martens is "DOCS."

Does Dr. Martens Pay Dividends? What’s The Current DOCS Dividend Yield?

Yes, DOCS Pays Dividends to its Shareholders. The current Dr. Martens dividend yield is 3.56%.

What Is the Current Dr. Martens Market Capitalisation?

As of today, Dr. Martens (London: DOCS) market cap is 686.23M GBP.

What Is Dr. Martens's (DOCS) Earnings Per Share (TTM)?

The Dr. Martens EPS is currently 0.02 (Trailing Twelve Months).

When Is the Next Dr. Martens Earnings Date?

Dr. Martens's next earnings report will be released on 26/11/2026.

Is DOCS a Buy or Sell From a Technical Analyst Perspective?

Based on today's Dr. Martens moving averages and other technical indicators, the daily buy/sell signal for DOCS stock is Strong Buy.

How Many Times Has Dr. Martens Stock Split?

Dr. Martens has split 0 times. (See the DOCS stock split history page for full effective split date and price information.)

How Many Employees Does Dr. Martens Have?

Dr. Martens has 2377 employees, based on their latest Companies House report.

What is the current trading status of Dr. Martens (London: DOCS)?

As of 04/07/2026, Dr. Martens (DOCS) is trading at a share price of 71.50 GBP, with a previous close of 71.70 GBP. The stock has fluctuated within a day range of 71.30 GBP to 73.00 GBP, while its 52-week range spans from 59.35 GBP to 100.80 GBP.

What Is Dr. Martens (DOCS) Price Target According to Analysts?

The average 12-month price target for Dr. Martens is 100.17 GBP, with a high estimate of 141 GBP and a low estimate of 70 GBP. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +40.09% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.